High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells

Documenti analoghi

• Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
  di: Nanjo, Shigeki, et al.
  Pubblicazione: (2013)
• Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
  di: Nakade, Junya, et al.
  Pubblicazione: (2014)
• Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
  di: Tanimoto, Azusa, et al.
  Pubblicazione: (2014)
• In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line
  di: Nanjo, Shigeki, et al.
  Pubblicazione: (2015)
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  di: Cross, Darren A. E., et al.
  Pubblicazione: (2014)